- Price
- $367.08 → $376.32(+2.5%)
- Discount
- 22.7% → 20.8%(−1.9 pts)
- Thesis
- UnitedHealth's 2025 cost spike, mainly in Medicare Advantage, forced a guidance withdrawal and a CEO change. It left the market pricing the stock as though the business is still troubled. The medical care ratio has since improved for several straight quarters. The case for a re-rating rests on that trend continuing rather than reversing. It also rests on the outcome of the Department of Justice's investigation into Medicare Advantage billing. A large fine or a forced change to risk-coding practices would cut future revenue. A resolution with limited financial impact would remove a source of negative attention that has weighed on the stock since 2024. New management is also selling down stakes in underperforming clinics, such as a September 2026 deal with TPG for Florida clinics, and cutting. It removed 30% of prior-authorization requirements startingon October 1, 2026. For 2027, it also ends Medicare Advantage plans with about 390,000 members, to leave less profitable markets. Both steps are meant to show the business model still works without the practices under scrutiny. The next Q3 2026 results, due October 13, 2026, will show whether the medical care ratio keeps improving into the back half of the year. If it does, and the DOJ matter resolves without a severe penalty, the discount can close over the next two to four quarters. If a large fine or forced billing changes arrive instead, the market's caution would prove correct, and the stock could stay discounted well into 2027.
- Recent events
- 2026-10-02: UnitedHealthcare said it will end Medicare Advantage plans for 2027 that cover about 390,000 members. It is leaving markets where its plans are less profitable. Affected members can choose another plan from October 15 to December 31, 2026.
2026-10-01: UnitedHealthcare removed 30% of its prior authorization requirements for most commercial, Medicare Advantage, Community Plan, Individual Exchange and Oxford plans.
2026-09-29: UnitedHealthcare named Robert Hunter its president. Hunter was CEO of UnitedHealthcare Government Programs. Tim Noel stays CEO of UnitedHealthcare.
2026-09-09: UnitedHealth sold a minority stake in a group of Florida WellMed clinics, which focus on older patients, to private-equity firm TPG. Optum keeps an ownership interest and stays in the local market.
2026-07-16: UnitedHealth reported Q2 2026 revenue of $112.0 billion. The medical care ratio improved to 86.7%, from 89.4% a year earlier, and management raised full-year guidance.
2025-05-13: UnitedHealth withdrew its full-year 2025 earnings guidance. CEO Andrew Witty stepped down, and Stephen Hemsley returned as CEO.